Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
公司代码BJDX
公司名称Bluejay Diagnostics Inc
上市日期Nov 10, 2021
CEODey (Neil)
员工数量7
证券类型Ordinary Share
年结日Nov 10
公司地址360 Massachusetts Avenue, Suite 203
城市ACTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01720
电话19786310152
网址https://bluejaydx.com/
公司代码BJDX
上市日期Nov 10, 2021
CEODey (Neil)